Patient Information
This report synthesizes clinical findings from a large-scale study involving 897 individuals clinically referred for GCK-MODY (glucokinase-maturity-onset diabetes of the young). The cohort represents a diverse group of patients typically presenting with lifelong, mild, stable fasting hyperglycaemia. For comparative analysis, the data also included 7,645 non-diabetic controls, 4,773 patients with Type 2 diabetes, and 601 participants with HNF1A-MODY. Additionally, 158 clinically unselected GCK variant carriers from the UK Biobank were evaluated to provide a population-based perspective. Clinical presentation typically involves an incidental finding of elevated blood glucose or HbA1c, often appearing early in life but occasionally remaining undiagnosed until routine screening.
Diagnosis
The diagnosis of GCK-MODY is established through the identification of a pathogenic or likely pathogenic variant in the GCK gene. This gene encodes the enzyme glucokinase, which serves as the pancreatic glucose sensor. Mutations raise the glucose threshold for insulin secretion, resulting in a higher-than-normal but stable set-point for fasting blood glucose. Key clinical findings include a modest elevation in fasting glucose (typically 5.5–8.0 mmol/l) and an HbA1c range generally between 38 mmol/mol and 60 mmol/mol. Unlike Type 1 diabetes, there is an absence of pancreatic autoantibodies, and unlike classic Type 2 diabetes, patients often lack metabolic syndrome features such as obesity or significant insulin resistance.
Differential Diagnosis
The differential diagnosis for GCK-MODY is broad and includes:
- Type 1 Diabetes (T1D): Ruled out by the stability of hyperglycaemia, lack of ketoacidosis, and absence of T1D-specific autoantibodies (GAD, IA-2, ZnT8).
- Type 2 Diabetes (T2D): Distinguished by the early onset, strong family history of mild hyperglycaemia, and lack of typical comorbidities. This study specifically noted that while T2D polygenic risk scores (PGS) are lower in GCK-MODY than in T2D patients, they still contribute to the overall phenotype.
- HNF1A-MODY: Another form of monogenic diabetes. While HNF1A-MODY patients also have a strong genetic driver, this study demonstrated that their polygenic background is primarily influenced by T2D risk scores, whereas GCK-MODY patients are more influenced by HbA1c and fasting glucose PGS.
- Stress Hyperglycaemia: Ruled out by the chronic and stable nature of the glucose elevation.
Treatment and Management
Management of GCK-MODY differs significantly from other forms of diabetes. Pharmacological treatment (insulin or oral hypoglycaemic agents) is generally not recommended or effective for lowering the glucose set-point, as the body naturally regulates back to its genetically determined threshold. Treatment focus remains on monitoring during pregnancy (to manage fetal growth risks) and lifestyle maintenance. However, this study suggests that management should consider the patient’s polygenic background. Patients in the top quintile of HbA1c PGS may show higher glycaemic levels, potentially leading to unnecessary treatment if the monogenic nature is not fully appreciated alongside their polygenic predisposition.
Outcome and Prognosis
The prognosis for GCK-MODY is generally excellent, with low risks of microvascular and macrovascular complications compared to Type 1 or Type 2 diabetes. However, clinical variability exists. The study found that GCK-MODY cases in the top HbA1c polygenic quintile had a 3-to-6-fold increased risk of exceeding the diabetes diagnostic threshold (HbA1c ≥48 mmol/mol). This implies that some GCK carriers are more likely to be clinically identified and labeled as ‘diabetic’ based on their polygenic risk, rather than the GCK mutation alone. Understanding this variability prevents over-medicalization while ensuring appropriate surveillance for those with higher baseline glycaemia.
Discussion
The significance of this case series lies in the debunking of the idea that monogenic diseases exist in a vacuum. While the GCK mutation provides the primary ‘hit’ for hyperglycaemia, the polygenic background (the cumulative effect of hundreds of common variants) acts as a powerful modifier. The study observed independent polygenic enrichment for HbA1c (including both glycaemic and non-glycaemic components), fasting glucose, and Type 2 diabetes in clinically referred GCK-MODY individuals compared with controls (0.16–0.33 SD higher).
Interestingly, the polygenic patterns of GCK-MODY and HNF1A-MODY are distinct. In HNF1A-MODY, only the T2D PGS contributed independently. In contrast, GCK-MODY showed a multi-faceted polygenic influence involving both specific glucose-sensing pathways and general T2D risk. This suggests an ‘aetiology-specific interaction’ where the underlying monogenic defect dictates which polygenic traits will most strongly influence the final clinical presentation.
For clinicians, these findings emphasize that a single genetic diagnosis may not explain the full spectrum of a patient’s laboratory results. In cases where a GCK-MODY patient presents with unexpectedly high HbA1c, the polygenic background should be considered as a contributing factor rather than assuming a secondary metabolic disease or mutation inefficacy. This study highlights the transition toward a more integrated ‘monogenic-plus-polygenic’ model of precision medicine.
References
1. Murray Leech J, Arni AM, Chundru VK, et al. Polygenic background contributes to GCK-MODY clinical presentation and glycaemic variability. Diabetologia. 2026. PMID: 41848901.
2. Hattersley AT, Patel KA. Precision diabetes: exactly what we need? Lancet Diabetes Endocrinol. 2017.
3. Colclough K, et al. Clinical and genetic classification of MODY. Current Diabetes Reports. 2014.
